Litigation

Recent Posts

$12.8M Verdict For Jaw Injury In Aredia/Zometa Case To Be Reduced To $1.14M
Posted on 24 Nov 2010 by Tom Moylan

WINSTON-SALEM, N.C. - (Mealey's) A North Carolina federal jury on Nov. 22 awarded $12,887,001 in an Aredia/Zometa jaw injury case, a verdict that will be reduced to $1,148,001 by North Carolina's limit on punitive damages ( Herbert Fussman, et... Read More

Jury Awards Plaintiff $10.4 Million For Injuries, Punitive Damages Linked To Novartis' Zometa
Posted on 5 Nov 2012 by Tom Moylan

CENTRAL ISLIP, N.Y. - (Mealey's) A New York federal jury on Nov. 2 found Novartis Pharmaceuticals Corp. liable for a woman's osteonecrosis of the jaw (ONJ) and awarded her $10.45 million, according to the parties ( Barbara Davids v. Novartis Pharmaceuticals... Read More

Novartis Wins Defense Verdict In Zometa Jaw Injury Trial
Posted on 26 May 2011 by Tom Moylan

BROOKLYN, N.Y. (Mealey's) A New York federal jury in the first federal Zometa trial found May 25 that the plaintiff did not prove by a preponderance of evidence that the Novartis Pharmaceuticals Corp. drug caused a decedent's osteonecrosis of... Read More

Another Specialty Pharmacy Settles Exjade False Claims Allegations For $45 Million
Posted on 1 May 2015 by Tom Moylan

NEW YORK —(Mealey’s) Specialty pharmacy Accredo Health Group Inc. on April 30 agreed to pay $45 million to settle a whistle-blower’s allegations that its efforts to push prescriptions for the iron chelation drug Exjade resulted in false... Read More

NYC Jury: Novartis Discriminated Against Women
Posted on 17 May 2010 by LexisNexis Litigation Resource Community Staff

NEW YORK - (AP) A jury has decided that the drug company Novartis AG engaged in a pattern of discrimination against women, paying them less than men and treating pregnant women unfavorably. The verdict was returned Monday in Manhattan federal court... Read More

Novartis To Pay $422.5M In Marketing, Kickbacks Case
Posted on 1 Oct 2010 by LexisNexis Litigation Resource Community Staff

PHILADELPHIA - (AP) Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials announced Thursday... Read More